<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350038</url>
  </required_header>
  <id_info>
    <org_study_id>L_8759</org_study_id>
    <nct_id>NCT00350038</nct_id>
  </id_info>
  <brief_title>Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions</brief_title>
  <official_title>Investigations of the Effects of Aprovel, Lipanor and Their Combination Onto the Endothelial Functions of Dyslipidemic Patients Measure by Laser Doppler Flow-Metry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The rationale of the study is to clarify whether the supplementation of irbesartan with
      ciprofibrate could increase the antihypertensive effect, could improve the endothelial
      functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations,
      onto the paraoxinase activity and on the CRP and insulin levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date>August 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular reactivity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reach of target blood pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of safety laboratory parameters</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofibrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypertensive + dyslipidemic + damaged endothelial function

        Exclusion Criteria:

          -  hepatic and kidney damage,

          -  IDDM (Insulin Dependent Diabetes Mellitus)

          -  Freckson V type hyperlipoproteinaemia

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>László Erős, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi-aventis, Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2006</study_first_submitted>
  <study_first_submitted_qc>July 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2006</study_first_posted>
  <last_update_submitted>January 18, 2008</last_update_submitted>
  <last_update_submitted_qc>January 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Ciprofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

